ZOVIRAX
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOVIRAX is an injectable antiviral small molecule approved in 1982 for the treatment of serious viral infections, primarily herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. The drug works by inhibiting viral DNA polymerase, preventing viral replication in infected cells. It is administered intravenously and remains a foundational therapy in acute viral infection management.
LOE Approaching
As LOE approaches, the brand team is likely consolidating focus on cost-efficiency and retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZOVIRAX offers limited career growth due to its mature, declining lifecycle stage and minimal current hiring activity. Roles on this brand typically focus on cost management, regulatory compliance, and maintaining market share against generics rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on ZOVIRAX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.